SCHEMBL1856563

SCHEMBL1856563

CCCCCCCCCCCCNS(=O)(=O)c1ccc(CN2C(=O)c3ccccc3C2=O)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.54
HTT P42858 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
RXFP1 Q9HBX9 3/20 0.48
BRD4 O60885 4/20 0.46
RECQL P46063 1/20 0.43
ASAH1 Q13510 1/20 0.43
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
CES1 P23141 2/20 0.39
CDC25A P30304 1/20 0.39
TP53 P04637 2/20 0.39
ALDH1A1 P00352 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4715407 0.79 SMN1; SMN2 (0.69) TSHRHTTSMN1; SMN2MEN1KMT2A
SCHEMBL28752191 0.78 KMT2A (0.52) TSHRHTTSMN1; SMN2MEN1KMT2A
SCHEMBL4715831 0.77 TSHR (0.60) TSHRHTTSMN1; SMN2MEN1KMT2A
SCHEMBL1853154 0.76 KMT2A (0.66) TSHRHTTSMN1; SMN2MEN1KMT2A
SCHEMBL4714622 0.74 TSHR (0.56) TSHRHTTSMN1; SMN2MEN1KMT2A
SCHEMBL1856043 0.74 SMN1; SMN2 (0.56) TSHRHTTSMN1; SMN2MEN1KMT2A
SCHEMBL2304654 0.73 CA1 (0.54) MEN1KMT2ARXFP1CA12CA9
SCHEMBL1855714 0.73 CASP3 (0.47) HTTMEN1KMT2ARXFP1RECQL
SCHEMBL4759742 0.72 CYP2D6 (0.45) TSHRHTTSMN1; SMN2MEN1KMT2A
SCHEMBL4715815 0.72 KMT2A (0.71) TSHRHTTSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1470102-B1 SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) MERCK SERONO SA (CH) 2011-05-25 EP disclosed
US-7592477-B2 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) LABORATOIRES SERONO SA (CH) 2009-09-22 US disclosed
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections LABORATOIRES SERONO SA (CH) 2009-01-15 US disclosed
EP-1986637-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS Laboratoires Serono SA (CH) 2008-11-05 EP disclosed
WO-2007093557-A1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS LABORATOIRES SERONO S.A. (CH) 2007-08-23 WO disclosed
US-20050124656-A1 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) APPLIED RESEARCH SYSTEMS ARS (NL) 2005-06-09 US disclosed
EP-1470102-A1 SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) Applied Research Systems ARS Holding N.V. (AN) 2004-10-27 EP disclosed
WO-2003064376-A1 SUBSTITUTED METHYLENE AMIDE DERIVATIVES AS MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018169-A1 Sulfonamide Derivatives for the Treatment of Bacterial Infections STS, TST, SULT1A1 TSHR 1632/4885HTT 4318/4885SMN1; SMN2 2147/4885
US-20050124656-A1 Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases(ptps) PTPRS, PTPA, PTPMT1 TSHR 1096/4885HTT 2944/4885SMN1; SMN2 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.